Fig. 2

Prevelance of Rituximab-associated hypogammaglobulinemia among various autoimmune diseases. Subjects with hypogammaglobulinemia were divided into two groups-based duration of hypogammaglobulinemia. Transient hypogammaglobulinemia (in light gray) was defined by low IgG for less than six months duration. In contrast, Persistent hypogammaglobulinemia (dark gray) was defined by low IgG for more than six months duration or the need for IgG replacement therapy. Patients with autoimmune CNS disease and ANCA vasculitis had a higher frequency of hypogammaglobulinemia (p = 0.006, Chi-square test). Most cases of hypogammaglobulinemia in the autoimmune CNS disease were persistent